Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02387359 · ClinicalTrials.gov registry record · Phase 3
The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C)
A Phase 3 study, sponsored by Bausch Health Americas.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,054
- Enrollment target
NCT02387359 is a Phase 3 study that has completed, run by Bausch Health Americas. The registered enrollment target is 1,054 participants.
The verdict
NCT02387359, a Phase 3 study, has completed, sponsored by Bausch Health Americas.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,054 participants
- Enrollment target
Study Summary
This study in patients with IBS-C is a randomized, double-blind, placebo-controlled, parallel-group clinical trial with 12 weeks of study drug therapy.
Interventions
- DRUG Placebo
- DRUG Plecanatide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,054 participants |
| Start Date | 2014-12 |
| Est. Completion | 2017-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02387359
The ClinicalTrials.gov registry entry for NCT02387359 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,054 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch Health Americas, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02387359 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02387359 about?
NCT02387359 is a clinical study titled "The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C)". This study in patients with IBS-C is a randomized, double-blind, placebo-controlled, parallel-group clinical trial with 12 weeks of study drug therapy.
What is the current status of trial NCT02387359?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,054 participants. The study started on 2014-12. Estimated completion is 2017-02.
What interventions are being tested in trial NCT02387359?
The interventions under investigation include: Placebo (DRUG), Plecanatide (DRUG).
Who is sponsoring clinical trial NCT02387359?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.